Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 9/2004

01-09-2004 | Comment

re: Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47:31–39

Authors: A. B. Jenkins, S. M. Furler, L. V. Campbell

Published in: Diabetologia | Issue 9/2004

Login to get access

Excerpt

To the Editor: Gastaldelli and co-workers [1] report an analysis of cross-sectional OGTT and euglycaemic clamp data from a sample with varying glucose tolerance (NGT, IGT, Type 2 diabetes) and conclude that “...beta cells in obese individuals function in an identical fashion to those of lean individuals.” This conclusion is supported by a lack of effect of obesity on the strong correlations between the insulin secretion/insulin resistance Index (\(\frac{{\Delta I_{{30}} }} {{\Delta G_{{30}} }} * \frac{1} {{IR}} \equiv \)Disposition Index [2]) and the fasting or 2-h glucose concentrations of the subjects studied. …
Literature
1.
Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47:31–39CrossRefPubMed
2.
Bergman RN (1989) Towards physiological understanding of glucose tolerance: minimal model approach. Diabetes 38:1512–1527PubMed
3.
Kriketos AD, Carey DG, Jenkins AB, Chisholm DJ, Furler SM, Campbell LV (2003) Central fat predicts deterioration of insulin secretion and fasting glycemia: 6-year follow-up of subjects at varying risk of Type 2 diabetes mellitus. Diabetic Med 20:294–300PubMed
Metadata
Title
re: Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47:31–39
Authors
A. B. Jenkins
S. M. Furler
L. V. Campbell
Publication date
01-09-2004
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2004
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-004-1478-4

Other articles of this Issue 9/2004

Diabetologia 9/2004 Go to the issue

Article

Albuminuria is a marker of increasing intracranial and extracranial vascular involvement in Type 2 diabetic Chinese patients

Article

Metabolic adaptations to chronic glucose infusion in rats

Authors’ Reply

Reply to Comment on: Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA (2004) Beta cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 43:31–39

Book reviews

R. Hanas (2002) Type 1 Diabetes in children, adolescents and young adults. How to become an expert on your own diabetes. Second edition. Class Publishing, London, UK. (ISBN 1 85959 078 0)

Article

Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells

EASD

EASD News Section September 2004
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits